Takeda Recognized in the 2019 Dow Jones Sustainability World Index


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score.

Also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year
Achieved more than double the average pharmaceutical industry sustainability score
Demonstrated significant year-over-year growth in score for strategy to improve access to medicines

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th consecutive year in the Dow Jones Sustainability Asia Pacific Index. The Dow Jones Sustainability Indices are an independent indication of the Company’s strong corporate environmental, social and governance (ESG) performance.


“Takeda’s commitment to creating and preserving value through environmental, social and governance initiatives is an important part of our role as a patient-centric and values-based global biopharmaceutical leader,” said Christophe Weber, President and CEO. “We understand the significance of sustainable business practices, and we are proud to be recognized for Takeda’s global impact and long-term commitment to building a brighter future.”


Takeda achieved more than double the average pharmaceutical industry sustainability score. Its strong scores in climate strategy and eco-efficiency support Takeda’s approach that a proactive environmental program focused on reducing environmental impacts leads to tangible economic benefits. Takeda also achieved double-digit year-over-year growth in its score for access to medicines – more than triple the industry average – based on its strategies to help strengthen evolving healthcare systems and tackle barriers that limit patient access.

About Takeda Pharmaceutical Company Limited


Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com

In addition to Dow Jones World and Asia Pacific Indices, Takeda has been selected by multiple benchmark ESG indices and recognitions:

 

Name of
Index or Rating

Company/
Organization

Country

History of
Inclusion

FTSE4Good Developed Index

FTSE Russell

UK

15th consecutive year

MSCI ESG Leaders Index

MSCI

U.S.

10th consecutive year

Ethibel EXCELLENCE Investment
Register

Forum Ethibel

BEL

From July 2017

Prime Status

ISS-Oekom

GER

2nd consecutive year

Industry Mover Sustainability Yearbook
Award 2019

RobecoSAM

CHE

From February 2019

Global 100 Most Sustainable
Corporations in the World Index

Corporate Knights

CND

4th consecutive year


About Takeda’s Sustainable Value Report


Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.

Tags : #takeda #pharma #recognition #dowjones #sustainability #worldindex

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Clinical Interventions in Chronic Hepatitis B and C: Antiviral Efficacy, Liver Fibrosis Scoring, and Monitoring August 11, 2026
Common Health Mistakes Indians Should Avoid: A Practical Guide to Everyday WellnessAugust 11, 2026
How to Build a Healthy Lifestyle After 40: A Practical Guide for Indian AdultsAugust 11, 2026
Milk Microbiome Could Hold New Clues to Lifelong Health, Experts SayAugust 10, 2026
Globally Renowned Dermatologist and Sesderma Founder Professor Dr. Gabriel Serrano to Visit India to Showcase Cutting-Edge Derma-Tech for Indian Skincare at Scientific Symposiums Hosted by Iberia PharmaceuticalsAugust 10, 2026
Sharda Hospital Celebrates World Breastfeeding Week with a Week-Long Awareness ProgrammeAugust 10, 2026
Swinburne University of Technology Opens Applications for Master of Engineering ScienceAugust 10, 2026
GLP-1 Receptor Agonists: A New Era in Weight Loss TreatmentAugust 10, 2026
Immunotherapy vs. Chemotherapy: Understanding the Mechanisms of Precision OncologyAugust 10, 2026
Mitigating Tech-Induced Ailments: Managing Screen Time, Sedentary Lifestyles, and Dry Eye SyndromeAugust 10, 2026
The Blueprint of Validation: Navigating Medical AI’s "Reckoning Year"August 10, 2026
The Future of Smart Hospitals: Redefining Healthcare Delivery in India August 10, 2026
Healthcare Data Security in India: Risks, Threats, and Best Practices for a Digital-First Health EcosystemAugust 10, 2026
The Science of Resilience: Psychological Strategies for Modern StressAugust 08, 2026
The Science of Fasting: 2026 Research on Autophagy and LongevityAugust 08, 2026
Early Markers of Insulin Resistance: Moving Beyond Fasting Blood SugarAugust 08, 2026
Healthcare Management Challenges in India: What Hospital Leaders Must Address NowAugust 08, 2026
Importance of Patient Safety: Why Every Hospital in India Must Prioritize ItAugust 08, 2026
Decoding Fatty Liver Disease: Symptoms, Reversibility, and the MASLD/NAFLD SpectrumAugust 07, 2026
Heart-Healthy Dietary Patterns: Translating Clinical Nutrition Guidelines into Daily MealsAugust 07, 2026